Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;2015:490295.
doi: 10.1155/2015/490295. Epub 2015 Mar 5.

TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy

Affiliations
Free PMC article

TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy

Helena Canhão et al. Biomed Res Int. .
Free PMC article

Abstract

Background: The aim of our work was to replicate, in a Southern European population, the association reported in Northern populations between PTPRC locus and response to anti-tumor necrosis factor (anti-TNF) treatment in rheumatoid arthritis (RA). We also looked at associations between five RA risk alleles and treatment response.

Methods: We evaluated associations between anti-TNF treatment responses assessed by DAS28 change and by EULAR response at six months in 383 Portuguese patients. Univariate and multivariate linear and logistic regression analyses were performed. In a second step to confirm our findings, we pooled our population with 265 Spanish patients.

Results: No association was found between PTPRC rs10919563 allele and anti-TNF treatment response, neither in Portuguese modeling for several clinical variables nor in the overall population combining Portuguese and Spanish patients. The minor allele for RA susceptibility, rs3761847 SNP in TRAF1/C5 region, was associated with a poor response in linear and logistic univariate and multivariate regression analyses. No association was observed with the other allellic variants. Results were confirmed in the pooled analysis.

Conclusion: This study did not replicate the association between PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants potentially influence anti-TNF treatment response.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Taylor P. C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Reviews Rheumatology. 2009;5(10):578–582. doi: 10.1038/nrrheum.2009.181. - DOI - PubMed
    1. Maini R., St Clair E. W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet. 1999;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. - DOI - PubMed
    1. McInnes I. B., Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine. 2011;365(23):2205–2219. doi: 10.1056/nejmra1004965. - DOI - PubMed
    1. Hetland M. L., Christensen I. J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism. 2010;62(1):22–32. doi: 10.1002/art.27227. - DOI - PubMed
    1. Hyrich K. L., Watson K. D., Silman A. J., Symmons D. P. M. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45(12):1558–1565. doi: 10.1093/rheumatology/kel149. - DOI - PubMed

Publication types

MeSH terms

Feedback